DII-235

N/A

Report date: 2026/04/28 20:00:22
NME

Base Information

Drug NameDII-235
Drug Alias NameDII235DII-235BW-20829
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionGene silencingApolipoprotein A-I inhibitors
TargetsApolipoprotein A-I
Therapy Area/IndicationsHyperlipoproteinemiasLipid Metabolism DisordersAtherosclerosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaGermany +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChina Novartis Institutes For Biomedical Research Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAsymchem Life Science (Tianjin) Co LtdArgo Biopharma Australia Pty LtdNovartis Pharma Ag +[4] 
Inactive CompaniesN/A
Active IndicationsHyperlipoproteinemiasLipid Metabolism DisordersAtherosclerosis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A